ecancermedicalscience

Special Issue

Biomarkers for precision immunotherapy in the metastatic setting: hope or reality?

3 Dec 2020
Elham Sajjadi, Konstantinos Venetis, Cristian Scatena, Nicola Fusco

Precision immunotherapy is a crucial approach to improve the efficacy of anti-cancer treatments, particularly in the metastatic setting. In this respect, accurate patient selection takes advantage of the multidimensional integration of patients’ clinical information and tumour-specific biomarkers status. Among these biomarkers, programmed death-ligand 1, tumour-infiltrating lymphocytes, microsatellite instability, mismatch repair and tumour mutational burden have been widely investigated. However, novel tumour-specific biomarkers and testing methods will further improve patients’ outcomes. Here, we discuss the currently available strategies for the implementation of a precision immunotherapy approach in the clinical management of metastatic solid tumours and highlight future perspectives.

Related Articles

Sasongko Hadi Priyono, Winardi Budiwinata, Budianto Tedjowitono, Effendy, Muhamad Daffa Ibnurasy Pratama
Rohini Sebastian, Josh Thomas Georgy, Arun George, Prisca Santhanam, Raiza Philip, Anjana Joel, Ajoy Oommen John, Deepa Susan Joy Philip, Divya Bala Thumaty, Thomas Alex Kodiatte, Ashish Singh, Rekha Pai
Sidhart Misra, Zainab Yusufali Motiwala, Ayyaz Mulla, Jagatheswaran Chinnathambi, Danny Darlington Carbin
Faiza Ahmed, Aqsa Amjad, Eman Anwar, Mohammad Saad Saleem Naviwala, Warda Saleem, Nawazish Zehra, Munira Moosajee, Yasmin Abdul Rashid
Muhammad Arif Hameed, Yasmin Abdul Rashid, Insia Ali, Waqas Ahmed Khan, Tasneem Dawood, Misbah Soomro, Mirza Rameez Samar